Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9042362 | 0.90 | ALDH1A1 (0.49) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL9043025 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL9041028 | 0.87 | ALDH1A1 (0.58) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL11492920 | 0.86 | FKBP1A (0.48) | ALDH1A1MEN1KMT2ACASP3CHRM2 | |
| SCHEMBL1831080 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL10750916 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MAPTMEN1KMT2ACASP3 | |
| SCHEMBL9044139 | 0.84 | ALDH1A1 (0.57) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL9042489 | 0.82 | ALDH1A1 (0.57) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL9040274 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL9043612 | 0.82 | POLB (0.46) | ALDH1A1KMT2AHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108033969-B | Oxoindolspirotetrahydrofuran compound and preparation method and application thereof | 中国医药集团总公司四川抗菌素工业研究所 | 2020-04-10 | — | — | CN | claimed |
| CN-108033969-B | Oxoindolspirotetrahydrofuran compound and preparation method and application thereof | 中国医药集团总公司四川抗菌素工业研究所 | 2020-04-10 | — | — | CN | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2318377-B1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-1888589-B1 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521557-B2 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1888589-A2 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127287-A2 | PYRROLOPYRIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-23 | — | — | US | disclosed |
| EP-0553130-B1 | PYRROLIDINE DIONE DERIVATIVES | PFIZER (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0553130-A1 | PYRROLIDINE DIONE DERIVATIVES. | PFIZER (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992006954-A2 | PYRROLIDINE DIONE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264457-A1 | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | ALDH1A1 799/4885MAPT 4195/4885MEN1 4674/4885 |
| US-20120165313-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | ALDH1A1 4303/4885MAPT 349/4885MEN1 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.